{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T04:07:36Z","timestamp":1746763656006,"version":"3.40.5"},"reference-count":113,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.farma.2024.11.008","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T20:10:26Z","timestamp":1735416626000},"page":"T169-T178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Drug dosing in obese critically ill patients, a literature review"],"prefix":"10.1016","volume":"49","author":[{"given":"Hector Carlos","family":"Garc\u00eda-D\u00edaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"S\u00e1nchez-Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Lalueza-Broto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Nuvials","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Queralt","family":"Gorgas-Torner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Dom\u00e9nech-Moral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2024.11.008_bb0005","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00134-019-05594-1","article-title":"Obesity in the critically ill: a narrative review","volume":"45","author":"Schetz","year":"2019","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.farma.2024.11.008_bb0015","series-title":"Report of a WHO Consultation. WHO Technical Report Series 894","article-title":"Obesity: preventing and managing the global epidemic","volume":"894","author":"OMS: Word Health Organisation","year":"2000"},{"issue":"5","key":"10.1016\/j.farma.2024.11.008_bb0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0025-7753(07)72531-9","article-title":"Consenso SEEDO 2007 para la evaluaci\u00f3n del sobrepeso y la obesidad y el establecimiento de criterios de intervenci\u00f3n terap\u00e9utica","volume":"128","author":"SEEDO","year":"2007","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/CIRCULATIONAHA.109.192575","article-title":"Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association","volume":"120","author":"Poirier","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.farma.2024.11.008_bb0030","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/QCO.0b013e328359a4c1","article-title":"Dosing of antibiotics in obesity","volume":"25","author":"Janson","year":"2012","journal-title":"Curr Opin Infect Dis."},{"issue":"9","key":"10.1016\/j.farma.2024.11.008_bb0035","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The origin of the \u201cideal\u201d body weight equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother."},{"issue":"5","key":"10.1016\/j.farma.2024.11.008_bb0040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF00542215","article-title":"Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients","volume":"24","author":"Bauer","year":"1983","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.farma.2024.11.008_bb0045","first-page":"331","article-title":"Drug dosing in special populations: obesity and geriatrics","volume":"45","author":"Barletta","year":"2017","journal-title":"Crit Care Med."},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0050","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jcpt.12200","article-title":"Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review","volume":"39","author":"Polso","year":"2014","journal-title":"J Clin Pharm Ther."},{"issue":"3","key":"10.1016\/j.farma.2024.11.008_bb0055","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1128\/AAC.02010-15","article-title":"Prospective, controlled study of acyclovir pharmacokinetics in obese patients","volume":"60","author":"Turner","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106871","article-title":"Comparison of dosing strategies in obese patients prescribed intravenous acyclovir and evaluation of rate of acute kidney injury","volume":"62","author":"Zelnicek","year":"2023","journal-title":"Int J Antimicrob Agents."},{"issue":"5","key":"10.1016\/j.farma.2024.11.008_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14134","article-title":"Safety and efficacy of weight-based ganciclovir dosing strategies in overweight\/obese patients","volume":"25","author":"Miller","year":"2023","journal-title":"Transpl Infect Dis."},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/QCO.0000000000000965","article-title":"Evidence supporting the use of therapeutic drug monitoring of ganciclovir in transplantation","volume":"36","author":"Wong","year":"2023","journal-title":"Curr Opin Infect Dis."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic drug monitoring of ganciclovir: where are we?","volume":"44","author":"M\u00e4rtson","year":"2022","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.farma.2024.11.008_bb0080","series-title":"Antiviral Agents. Encyclopedia of Microbiology","first-page":"223","author":"Paintsil","year":"2009"},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0085","first-page":"227","article-title":"Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review","volume":"6","author":"Velissaris","year":"2014","journal-title":"J Clin Med Res."},{"issue":"11","key":"10.1016\/j.farma.2024.11.008_bb0090","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/jac\/dkaa312","article-title":"Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function","volume":"75","author":"Smit","year":"2020","journal-title":"J Antimicrob Chemother."},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0095","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents."},{"issue":"11","key":"10.1016\/j.farma.2024.11.008_bb0100","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/14787210.2020.1788387","article-title":"Therapeutic drug monitoring of \u03b2-lactam antibiotics in the ICU","volume":"18","author":"Dhaese","year":"2020","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2110-5820-2-35","article-title":"Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review","volume":"2","author":"Sime","year":"2012","journal-title":"Ann Intensive Care."},{"key":"10.1016\/j.farma.2024.11.008_bb0110","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/phar.2769","article-title":"Comprehensive guidance for antibiotic dosing in obese adults: 2022 update","volume":"43","author":"Meng","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.farma.2024.11.008_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/diseases8030027","article-title":"Impact of obesity on ceftriaxone efficacy","volume":"8","author":"Barber","year":"2020","journal-title":"Diseases"},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0120","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01663-23","article-title":"Impact of hypoalbuminemia on clinical outcomes among patients with obesity treated with ceftriaxone","volume":"68","author":"Arensman Hannan","year":"2024","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.farma.2024.11.008_bb0125","article-title":"Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections","volume":"11","author":"El Ghali","year":"2024","journal-title":"MicrobiolSpectr"},{"key":"10.1016\/j.farma.2024.11.008_bb0130","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"2","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.farma.2024.11.008_bb0135","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/bcp.15782","article-title":"Ertapenem blood concentration: a retrospective cohort study to analyse risk of neurotoxicity","volume":"89","author":"Campany-Herrero","year":"2023","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimising antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0145","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cmi.2014.08.003","article-title":"Leibovici L.et al., Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study","volume":"21","author":"Zusman","year":"2015","journal-title":"Clin Microbiol Infect."},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0150","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/AAC.50.4.1222-1227.2006","article-title":"Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults","volume":"50","author":"Chen","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.farma.2024.11.008_bb0155","article-title":"Dosificaci\u00f3n de antimicrobianos en situaciones especiales: Ajuste en obesidad","author":"Mu\u00f1oz Burgos","year":"2019","journal-title":"Gu\u00eda Prioam."},{"issue":"5","key":"10.1016\/j.farma.2024.11.008_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01719-23","article-title":"Rodr\u00edguez-Jato T.et al., Updated antimicrobial dosing recommendations for obese patients","volume":"68","author":"Castro-Balado","year":"2024","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.farma.2024.11.008_bb0165","article-title":"Dosing of ertapenem in an extreme obesity: a case report of 250kg patient","volume":"2017","author":"Lass","year":"2017","journal-title":"Case Rep Crit Care."},{"issue":"7","key":"10.1016\/j.farma.2024.11.008_bb0170","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11695-013-0879-1","article-title":"Serum in vivo and in vitro activity of single dose of ertapenem in surgical obese patients for prevention of SSIs","volume":"23","author":"de Werra","year":"2013","journal-title":"Obes Surg."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/sur.2010.095","article-title":"Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalised adults: comparison of ertapenem with piperacillin-tazobactam","volume":"13","author":"Zakrison","year":"2012","journal-title":"Surg Infect (Larchmt)."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0180","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01325-21","article-title":"Clinical outcomes with ertapenem for pneumonia in obese versus nonobese patients","volume":"66","author":"Caputo","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0185","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00228-018-2597-z","article-title":"Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations","volume":"75","author":"Chambers","year":"2019","journal-title":"Eur J Clin Pharmacol."},{"issue":"8","key":"10.1016\/j.farma.2024.11.008_bb0190","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s40262-022-01130-5","article-title":"Ciprofloxacin pharmacokinetics after oral and intravenous administration in (morbidly) obese and non-obese individuals: a prospective clinical study","volume":"61","author":"van Rhee","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.farma.2024.11.008_bb0195","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1345\/aph.1P234","article-title":"High-dose ciprofloxacin for serious Gram-negative infection in an obese, critically ill patient receiving continuous venovenous haemodiafiltration","volume":"44","author":"Utrup","year":"2010","journal-title":"Ann Pharmacother."},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0200","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/jac\/dkw043","article-title":"Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother."},{"issue":"8","key":"10.1016\/j.farma.2024.11.008_bb0205","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40262-014-0154-1","article-title":"Levofloxacin dosing regimen in severely morbidly obese patients (BMI \u226540\u202fkg\/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimised by therapeutic drug monitoring","volume":"53","author":"Pai","year":"2014","journal-title":"Clin Pharmacokinet."},{"issue":"7","key":"10.1016\/j.farma.2024.11.008_bb0210","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jac\/dkr146","article-title":"Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient","volume":"66","author":"Luque","year":"2011","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0215","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/QCO.0b013e328359a4c1","article-title":"Dosing of antibiotics in obesity","volume":"25","author":"Janson","year":"2012","journal-title":"Curr Opin Infect Dis."},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0220","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.farma.2024.11.008_bb0225","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40262-017-0606-5","article-title":"Population pharmacokinetics and dosing considerations for the use of linezolid in overweight and obese adult patients","volume":"57","author":"Cojutti","year":"2018","journal-title":"Clin Pharmacokinet."},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0230","doi-asserted-by":"crossref","first-page":"e01619","DOI":"10.1128\/AAC.01619-20","article-title":"Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections","volume":"65","author":"Blackman","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0235","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/jcm9041067","article-title":"Linezolid concentrations in plasma and subcutaneous tissue are reduced in obese patients, resulting in a higher risk of underdosing in critically ill patients: a controlled clinical pharmacokinetic study","volume":"9","author":"Simon","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.farma.2024.11.008_bb0240","doi-asserted-by":"crossref","first-page":"967311","DOI":"10.3389\/fpubh.2022.967311","article-title":"Expert consensus statement on therapeutic drug monitoring and individualization of linezolid","volume":"10","author":"Lin","year":"2022","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0245","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-022-01125-2","article-title":"A review of population pharmacokinetic analyses of linezolid [published correction appears in Clin Pharmacokinet. 2023 Sep;62(9):1331. 10.1007\/s40262-023-01295-7]","volume":"61","author":"Band\u00edn-Vilar","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0250","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2125.2012.04292.x","article-title":"Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis","volume":"74","author":"Bouazza","year":"2012","journal-title":"Br J Clin Pharmacol"},{"year":"2011","author":"Ministerio de Sanidad, Servicios Sociales e Igualdad","series-title":"Ficha t\u00e9cnica: Clindamicina intravenoso","key":"10.1016\/j.farma.2024.11.008_bb0255"},{"key":"10.1016\/j.farma.2024.11.008_bb0260","article-title":"Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight","volume":"6","author":"Fox","year":"2019","journal-title":"Ther Adv Infect Dis"},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0265","first-page":"2882","article-title":"Efficacy and safety of weight-based dosing of daptomycin in obese patients: a systematic review","volume":"21","author":"Wali","year":"2023","journal-title":"Pharm Pract."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0270","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/0091270004269562","article-title":"The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects","volume":"45","author":"Dvorchik","year":"2005","journal-title":"J Clin Pharmacol."},{"issue":"8","key":"10.1016\/j.farma.2024.11.008_bb0275","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1128\/AAC.00059-07","article-title":"Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.farma.2024.11.008_bb0280","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bcpt.13618","article-title":"Risk of muscle toxicity events for daptomycin with and without statins: analysis of the Japanese Adverse Event Report database","volume":"129","author":"Yamada","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"12","key":"10.1016\/j.farma.2024.11.008_bb0285","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/phar.1298","article-title":"Sheldon M.A.,Caulder C.R.,et al., Safety and effectiveness of daptomycin across a hospitalised obese population: results of a multicenter investigation in the southeastern United States","volume":"33","author":"Bookstaver","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0290","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Fana C.,et al., Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.farma.2024.11.008_bb0295","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1128\/AAC.01088-16","article-title":"Lassig-Smith M.,et al., Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients","volume":"60","author":"Alobaid","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"10.1016\/j.farma.2024.11.008_bb0300","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/jac\/dkac160","article-title":"Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults","volume":"77","author":"Chen","year":"2022","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1586\/14787210.2016.1128822","article-title":"Dosing of antifungal agents in obese people","volume":"14","author":"Payne","year":"2016","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0310","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/jac\/dkz546","article-title":"Verweij P.E.,et al., Implications for IV posaconazole dosing in the era of obesity","volume":"75","author":"Wasmann","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.farma.2024.11.008_bb0315","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12281-019-0335-3","article-title":"Dosing antifungals in obesity: a literature review","volume":"13","author":"Amsden","year":"2019","journal-title":"Curr Fungal Infect Rep."},{"key":"10.1016\/j.farma.2024.11.008_bb0320","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"H\u00f6hl","year":"2022","journal-title":"Mycoses"},{"issue":"7","key":"10.1016\/j.farma.2024.11.008_bb0325","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3390\/antibiotics12071099","article-title":"Therapeutic drug monitoring of antimicrobials in critically ill obese patients","volume":"12","author":"Gorham","year":"2023","journal-title":"Antibiotics (Basel)."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0330","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FTD.0000000000000931","article-title":"Therapeutic drug monitoring of the echinocandin antifungal agents: is there a role in clinical practice? A position statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic","volume":"44","author":"Kim","year":"2022","journal-title":"Drug Monitoring and Clinical Toxicology, Ther Drug Monit."},{"key":"10.1016\/j.farma.2024.11.008_bb0335","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13054-018-2019-8","article-title":"Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients","volume":"22","author":"Maseda","year":"2018","journal-title":"Crit Care."},{"issue":"7","key":"10.1016\/j.farma.2024.11.008_bb0340","doi-asserted-by":"crossref","first-page":"e00063","DOI":"10.1128\/AAC.00063-18","article-title":"Pharmacokinetics of anidulafungin in obese and normal-weight adults","volume":"62","author":"Wasmann","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.farma.2024.11.008_bb0345","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1128\/AAC.01473-12","article-title":"Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections","volume":"57","author":"Liu","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"10.1016\/j.farma.2024.11.008_bb0350","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02366-20","article-title":"Evaluation of total body weight versus adjusted body weight liposomal amphotericin B dosing in obese patients","volume":"65","author":"Ting","year":"2021","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"10.1016\/j.farma.2024.11.008_bb0355","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/cid\/ciz885","article-title":"de Beer Y.M.,et al., Fixed dosing of liposomal amphotericin B in morbidly obese individuals","volume":"70","author":"Wasmann","year":"2020","journal-title":"Clin Infect Dis."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0360","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13054-021-03495-8","article-title":"Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis","volume":"25","author":"Erstad","year":"2021","journal-title":"Crit Care."},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0365","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14529","article-title":"Comparing weight-based dosing of tacrolimus XR in obese and non-obese renal transplant recipients","volume":"36","author":"Breslin","year":"2022","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0370","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/jorc.12339","article-title":"Body weight-based initial dosing of tacrolimus in renal transplantation: is this an ideal approach?","volume":"47","author":"Chinnadurai","year":"2021","journal-title":"J Ren Care."},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0375","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000644","article-title":"Overweight kidney transplant recipients are at risk of being overdosed following standard bodyweight-based tacrolimus starting dose","volume":"3","author":"Andrews","year":"2017","journal-title":"Transplant Direct"},{"issue":"5","key":"10.1016\/j.farma.2024.11.008_bb0380","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00228-011-1150-0","article-title":"The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation","volume":"68","author":"Stratta","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0385","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/imj.14043","article-title":"Weight-based tacrolimus trough concentrations post liver transplant","volume":"49","author":"Liu","year":"2019","journal-title":"Intern Med J"},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0390","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/FTD.0b013e3181d18baa","article-title":"Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial","volume":"32","author":"Kaplan","year":"2010","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.farma.2024.11.008_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108833","article-title":"Evaluation of phenytoin loading doses in overweight patients using actual versus adjusted body weight","volume":"134","author":"Keats","year":"2022","journal-title":"Epilepsy Behav."},{"issue":"5","key":"10.1016\/j.farma.2024.11.008_bb0400","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0000000000000550","article-title":"Influence of sex, age, and weight on levetiracetam pharmacokinetics","volume":"40","author":"Alzueta","year":"2018","journal-title":"Ther Drug Monit."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0405","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12883-023-03515-w","article-title":"Enhanced renal clearance impacts levetiracetam concentrations in patients with traumatic brain injury with and without augmented renal clearance","volume":"24","author":"Cook","year":"2024","journal-title":"BMC Neurol."},{"issue":"5","key":"10.1016\/j.farma.2024.11.008_bb0410","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40262-020-00979-8","article-title":"Population pharmacokinetics of levetiracetam in patients with traumatic brain injury and subarachnoid haemorrhage exhibiting augmented renal clearance","volume":"60","author":"Sime","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.farma.2024.11.008_bb0415","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1060028017694376","article-title":"Impact of norepinephrine weight-based dosing compared with non-weight-based dosing in achieving time to goal mean arterial pressure in obese patients with septic shock","volume":"51","author":"Droege","year":"2017","journal-title":"Ann Pharmacother."},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0420","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0885066618768180","article-title":"Clinical outcomes of weight-based norepinephrine dosing in underweight and morbidly obese patients: a propensity-matched analysis","volume":"35","author":"Kotecha","year":"2020","journal-title":"J Intensive Care Med."},{"issue":"10","key":"10.1016\/j.farma.2024.11.008_bb0425","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/1060028016656384","article-title":"Effect of body weight on hemodynamic response in patients receiving fixed-dose vasopressin for septic shock","volume":"50","author":"Hodge","year":"2016","journal-title":"Ann Pharmacother."},{"issue":"12","key":"10.1016\/j.farma.2024.11.008_bb0430","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1177\/10600280211007213","article-title":"Effect of vasopressin dose on hemodynamic response in obese patients with septic shock: a retrospective observational study","volume":"55","author":"Dubrawka","year":"2021","journal-title":"Ann Pharmacother."},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0435","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jcrc.2014.11.020","article-title":"Unfractionated heparin dosing for therapeutic anticoagulation in critically ill obese adults","volume":"30","author":"Hohner","year":"2015","journal-title":"J Crit Care."},{"key":"10.1016\/j.farma.2024.11.008_bb0440","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1055\/s-0040-1718405","article-title":"Dosage of anticoagulants in obesity: recommendations based on a systematic review","volume":"46","author":"Abildgaarrd","year":"2020","journal-title":"Semin Thromb Hemost."},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0445","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/0018578719848732","article-title":"Prophylactic enoxaparin dosing in obese orthopaedic patients: a literatura search","volume":"55","author":"Tran","year":"2020","journal-title":"Hosp Pharm."},{"issue":"9","key":"10.1016\/j.farma.2024.11.008_bb0450","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1177\/1060028018768449","article-title":"Enoxaparin dosing at extremes of weight: literature review and dosing recommendations","volume":"52","author":"Sebaaly","year":"2018","journal-title":"Ann Pharmacother."},{"issue":"4","key":"10.1016\/j.farma.2024.11.008_bb0455","article-title":"Low prevalence of thrombosis prophylaxis dose adjustments highlights implications for patient safety","volume":"12","author":"Anthony Hawkins","year":"2021","journal-title":"Innov Pharm."},{"key":"10.1016\/j.farma.2024.11.008_bb0460","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.thromres.2018.07.027","article-title":"Heparin dosing for venous thromboembolism prophylaxis in obese hospitalised patients: an observational study","volume":"169","author":"Patanwala","year":"2018","journal-title":"Thromb Res."},{"key":"10.1016\/j.farma.2024.11.008_bb0465","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-024-02951-w","article-title":"A systematic review of therapeutic enoxaparin dosing in obesity","author":"Chilbert","year":"2024","journal-title":"J Thromb Thrombolysis."},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0470","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0310057X20968573","article-title":"Dosing of neuromuscular blocking agents in patients with obesity: a narrative review","volume":"49","author":"Erstad","year":"2021","journal-title":"Anaesth Intensive Care."},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0475","first-page":"563","article-title":"Comparison of the onset of action, maintenance, and recovery of three weight-based dosing of cisatracurium in patients with morbid obesity in laparoscopic bariatric surgery: a randomised clinical trial","volume":"48","author":"Rokhtabnak","year":"2023","journal-title":"Iran J Med Sci."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0480","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5811\/WESTJEM.60713","article-title":"Rocuronium dosing by ideal vs total body weight in obesity: a prospective, observational non-inferiority study","volume":"25","author":"McDowell","year":"2024","journal-title":"West J Emerg Med"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2024.11.008_bb0485","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/bja\/aeq312","article-title":"Dose adjustment of anaesthetics in the morbidly obese","volume":"105","author":"Ingrande","year":"2010","journal-title":"Br J Anaesth."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0490","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s13054-020-03040-z","article-title":"Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium","volume":"24","author":"Erstad","year":"2020","journal-title":"Crit Care."},{"issue":"6","key":"10.1016\/j.farma.2024.11.008_bb0495","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0018578719851452","article-title":"Adjusted vs total body weight-based dosing of sedation and analgesia used in the intensive care unit","volume":"55","author":"Yeary","year":"2020","journal-title":"Hosp Pharm."},{"issue":"3","key":"10.1016\/j.farma.2024.11.008_bb0500","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/10600280221108429","article-title":"Adherence to sedation targets with weight-based propofol and dexmedetomidine in patients with morbid obesity","volume":"57","author":"Hayes","year":"2023","journal-title":"Ann Pharmacother."},{"issue":"5","key":"10.1016\/j.farma.2024.11.008_bb0505","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12630-017-0852-x","article-title":"Optimal propofol induction dose in morbidly obese patients: a randomised controlled trial comparing the bispectral index and lean body weight scalar","volume":"64","author":"Subramani","year":"2017","journal-title":"Can J Anaesth."},{"issue":"5","key":"10.1016\/j.farma.2024.11.008_bb0510","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12630-017-0853-9","article-title":"Practical dosing of propofol in morbidly obese patients","volume":"64","author":"Tsui","year":"2017","journal-title":"Can J Anaesth."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0515","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1213\/ANE.0b013e3181f6d9c0","article-title":"Lean body weight scalar for the anaesthetic induction dose of propofol in morbidly obese subjects","volume":"113","author":"Ingrande","year":"2011","journal-title":"Anesth Analg."},{"issue":"1","key":"10.1016\/j.farma.2024.11.008_bb0520","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/08971900211021578","article-title":"Evaluation of dexmedetomidine dosing in obese critically ill patients","volume":"36","author":"Atyia","year":"2023","journal-title":"J Pharm Pract."},{"issue":"2","key":"10.1016\/j.farma.2024.11.008_bb0525","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/ijciis.ijciis_74_22","article-title":"Retrospective evaluation of dexmedetomidine dosing in a cohort of neurologically injured obese critically ill patients","volume":"13","author":"He","year":"2023","journal-title":"Int J Crit Illn Inj Sci."},{"year":"2023","article-title":"Estudio ENE-COVID: Situaci\u00f3n ponderal de la poblaci\u00f3n adulta en Espa\u00f1a","series-title":"Informe. Agencia Espa\u00f1ola de Seguridad Alimentaria y Nutrici\u00f3n (Ministerio de Consumo)","key":"10.1016\/j.farma.2024.11.008_bb0530"},{"issue":"7","key":"10.1016\/j.farma.2024.11.008_bb0535","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.medcli.2020.06.009","article-title":"Relationship between obesity, diabetes and ICU admission in COVID-19 patients. Relaci\u00f3n entre obesidad, diabetes e ingreso en UCI en pacientes COVID-19","volume":"155","author":"Fern\u00e1ndez Garc\u00eda","year":"2020","journal-title":"Med Clin (Barc)."},{"issue":"7","key":"10.1016\/j.farma.2024.11.008_bb0540","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/oby.22831","article-title":"High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation [published correction appears in obesity (Silver Spring). 2020 Oct;28(10):1994]","volume":"28","author":"Simonnet","year":"2020","journal-title":"Obesity (Silver Spring)"},{"year":"2020","author":"INARC","series-title":"Report on 2249 Patients Critically Ill with COVID-19","key":"10.1016\/j.farma.2024.11.008_bb0545"},{"key":"10.1016\/j.farma.2024.11.008_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115281","article-title":"Pharmacokinetics of obese adults: not only an increase in weight","volume":"166","author":"Gouju","year":"2023","journal-title":"Biomed Pharmacother."},{"issue":"Suppl 1","key":"10.1016\/j.farma.2024.11.008_bb0555","first-page":"S64","article-title":"Terapia antimicrobiana personalizada en pacientes cr\u00edticos y en edad avanzada","volume":"45","author":"Grau","year":"2021","journal-title":"Farm Hosp."},{"issue":"7","key":"10.1016\/j.farma.2024.11.008_bb0560","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ajhp\/zxaa022","article-title":"Availability of information for dosing commonly used medications in special ICU populations","volume":"77","author":"Eastman","year":"2020","journal-title":"Am J Health Syst Pharm."},{"issue":"22","key":"10.1016\/j.farma.2024.11.008_bb0565","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2146\/ajhp100226","article-title":"Availability of information for dosing injectable medications in underweight or obese patients","volume":"67","author":"Jacques","year":"2010","journal-title":"Am J Health Syst Pharm."}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324001910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324001910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T02:18:54Z","timestamp":1746757134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324001910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1130634324001910"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.11.008","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Drug dosing in obese critically ill patients, a literature review","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.09.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}